drugset / Trial / NCT02198352

Study to Determine Tolerability After Intravenous Administration of BIBN 4096 BS in Healthy Male and Female Volunteers

NCT02198352 ↗

Phase 1 Completed 55 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of the present study is to obtain information about the safety, tolerability and pharmacokinetics of BIBN 4096 BS after single intravenous administration of increasing doses in healthy male and female volunteers

Timeline

Start
1998-06
Primary completion
1998-08
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject OLCEGEPANT Small molecule — Intravenous

Indications

No indication recorded.